ストックスクリーナーアプリを入手
3.88
10.39%
-0.45
アフターアワーズ：
3.89
0.01
+0.26%
前日終値:
$4.33
開ける：
$4.27
24時間の取引高:
308.39K
Relative Volume:
0.51
時価総額：
$339.25M
収益：
$33.98M
当期純損益:
$-95.10M
株価収益率:
-0.3877
EPS:
-10.0072
ネットキャッシュフロー:
$-106.13M
1週間 パフォーマンス:
+4.86%
1か月 パフォーマンス:
+15.13%
6か月 パフォーマンス:
+19.02%
1年 パフォーマンス:
-62.22%
1日の値動き範囲:
$3.87
$4.27
1週間の範囲:
$3.65
$4.83
52週間の値動き範囲:
$1.35
$10.49
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.88 | 378.60M | 33.98M | -95.10M | -106.13M | -10.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.13 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.61 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.85 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology - Investing.com
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Summary: Is X4 Pharmaceuticals Inc impacted by rising ratesTrade Analysis Report & Stepwise Swing Trade Plans - baoquankhu1.vn
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Guggenheim initiates X4 Pharmaceuticals stock with buy rating - Investing.com Australia
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - Yahoo Finance
Layoff Tracker: Vertex Terminates 20 in Reorganization Push - BioSpace
Xenon Pharmaceuticals to Announce Topline Data from Phase 3 X-TOLE2 Study of Azetukalner for Focal Onset Seizures - Quiver Quantitative
Phase 3 seizure drug data Monday in Xenon focal onset study - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Can X4 Pharmaceuticals Inc lead its sector in growthJuly 2025 Reactions & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - The Manila Times
XFOR Technical Analysis & Stock Price Forecast - Intellectia AI
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
XFOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
Biotech X4 hires staff with stock options priced at $3.44 - Stock Titan
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
69,248 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Thornburg Investment Management Inc. - MarketBeat
EMA backs potential first WHIM treatment in EU after 60% infection drop - Stock Titan
XFOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
X4 Pharmaceuticals (XFOR) Price Target Increased by 16.67% to 9.52 - Nasdaq
ETF Watch: How much upside does X4 Pharmaceuticals Inc haveJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Final Week & Verified Chart Pattern Trade Signals - mfd.ru
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and SchizophreniaA New Chemical Entity Opening New Horizons in Psychiatric Innovation - Morningstar
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Tax-related stock sale by Rocket Pharma (RCKT) CEO Gaurav Shah - Stock Titan
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Artal Participations boosts Lexicon (NASDAQ: LXRX) stake with Series B preferred buy - Stock Titan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
AI Stocks: Will CADL stock go up in YEAR2025 Risk Factors & Precise Trade Entry Recommendations - baoquankhu1.vn
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Rocket Pharmaceuticals (RCKT) CEO sells shares to cover RSU taxes - Stock Titan
Can X4 Pharmaceuticals Inc. lead its sector in growthPortfolio Gains Summary & AI Based Trade Execution Alerts - mfd.ru
[SCHEDULE 13G/A] X4 Pharmaceuticals, Inc Amended Passive Investment Disclosure - Stock Titan
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Bain Capital Life Sciences reports 8.41% X4 (XFOR) stake including large warrant position - Stock Titan
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is X4 Pharmaceuticals Inc. forming a bullish divergenceWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - TMX Newsfile
How X4 Pharmaceuticals Inc. stock trades before earningsQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
1.76%
0.09%
大文字化:
|
ボリューム (24 時間):